Regulatory delays in bone marrow transplant approval
Government approval for bone marrow transplant unit is delayed due to procedural issues, pushing revenue contribution to FY28.
ASARFIHOSPITAL / Q4-FY26 / risks
Keep the risk register visible.
Asarfi Hospital · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Volatility in government scheme reimbursements
Changes in government scheme approval systems caused a decline in cancer patient volumes in Q4; future volatility could impact revenue.
Elevated receivables and working capital pressure
Receivables aging of 6-7 months due to delayed government reimbursements may keep working capital elevated.
Execution risk in aggressive growth targets
The FY27 revenue target of 260 crore and 500+ bed capacity by 2028 appear aggressive given current run-rate and regulatory hurdles.